Intuitive Surgical initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Intuitive Surgical with a Buy rating and $500 price target. There remains “ample room” for Intuitive to drive increased penetration of robotic-assisted surgery, enabled by its next generation product advances, the analyst tells investors in a research note. The firm says the company is at the early stages of building a fully-integrated care delivery model to include intervention, data analytics, and eventually automating surgery.